Actinium Pharmaceuticals

Filed a patent for "calreticulin nanobodies" on Tue, March 28, 2023

Filed a patent for "bifunctional chelators and conjugates" on Thu, August 1, 2024

Filed a patent for "humanized anti-cd45 antibodies" on Fri, September 9, 2022

Filed a patent for "humanized anti-cd45 antibodies" on Mon, September 19, 2022

Filed a patent for "bifunctional chelators" on Thu, September 22, 2022

Filed a patent for "dr5 radioimmunotherapy in the treatment of solid cancers" on Thu, September 28, 2023

Filed a patent for "bifunctional chelators and conjugates" on Wed, March 1, 2023

Filed a patent for "trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers" on Thu, December 7, 2023

Filed a patent for "calreticulin nanobodies" on Thu, December 28, 2023

Filed a patent for "humanized anti-cd45 antibodies" on Thu, January 11, 2024

Filed a patent for "bifunctional chelators and conjugates" on Thu, March 14, 2024

Filed a patent for "bifunctional chelators and conjugates" on Thu, February 15, 2024

Filed a patent for "anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies" on Thu, May 16, 2024

Filed a patent for "radiolabeling of anti-cd45 immunoglobulin and methods of use thereof" on Thu, December 1, 2022